Windtree Therapeutics ( (WINT) ) just unveiled an update.
Windtree Therapeutics has appointed Leanne Kelly to its board of directors as an independent director and chair of the audit committee, aiming to resolve a compliance deficiency with Nasdaq’s requirements. Kelly’s extensive experience in finance and leadership across life science, technology, and e-Commerce sectors is expected to strengthen Windtree’s board as the company embarks on a new strategy to acquire small biotech firms with FDA-approved products, enhancing its market positioning.
More about Windtree Therapeutics
Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. The company’s portfolio includes istaroxime, a Phase II candidate for acute heart failure, preclinical SERCA2a activators for heart failure, and preclinical precision aPKCi inhibitors for oncology applications. Windtree also operates a licensing business model with partnership out-licenses.
YTD Price Performance: -24.78%
Average Trading Volume: 2,183,853
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.82M
See more insights into WINT stock on TipRanks’ Stock Analysis page.